Kidney & related urinary system cancer, malignant (ICD10 C64-C66 & C68): combined sexes
This is the EUROCARE definition used for kidney cancer, and includes other parts of the urinary tract (with the exception of bladder)
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
50.7% |
52.0% |
57.5% |
60.1% |
||||||||
|
(unstandardized) |
(46.8-54.4%) |
(48.9-55.0%) |
(54.0-60.8%) |
(56.5-63.5%) |
||||||||
|
all 15-99 |
47.3% |
48.6% |
53.7% |
56.4% |
54.1% |
55.7% |
||||||
|
(age-standardized)# |
(39.4-54.9%) |
(42.2-54.8%) |
(46.8-60.4%) |
(46.9-60.8%) |
(47.8-61.2%) |
(53.6-58.0%) |
||||||
|
15-44 |
72.4% |
77.5% |
79.2% |
85.4% |
||||||||
|
(59.5-81.8%) |
(68.4-84.4%) |
(70.9-85.5%) |
(74.8-91.9%) |
|||||||||
|
45-54 |
62.2% |
64.9% |
70.9% |
72.7% |
||||||||
|
(53.6-69.6%) |
(57.8-71.1%) |
(63.7-77.0%) |
(64.0-79.6%) |
|||||||||
|
55-64 |
57.1% |
51.8% |
62.1% |
66.7% |
||||||||
|
(49.9-63.6%) |
(46.1-57.2%) |
(55.4-68.2%) |
(60.2-72.6%) |
|||||||||
|
65-74 |
42.5% |
48.1% |
51.9% |
54.4% |
||||||||
|
(35.7-49.2%) |
(42.5-53.5%) |
(45.9-57.7%) |
(47.7-60.7%) |
|||||||||
|
75-99 |
32.2% |
32.9% |
35.6% |
36.4% |
||||||||
|
(24.0-41.2%) |
(26.1-40.2%) |
(28.0-43.8%) |
(28.4-44.9%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|